Q2 EPS Estimate for Precision BioSciences Reduced by Analyst

Precision BioSciences, Inc. (NASDAQ:DTIL) – Investment analysts at HC Wainwright dropped their Q2 2026 earnings per share estimates for shares of Precision BioSciences in a research note issued to investors on Monday, August 3rd. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.57) per share for the quarter, down from their previous forecast of ($0.50). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Precision BioSciences’ current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for Precision BioSciences’ Q3 2026 earnings at ($0.58) EPS, Q4 2026 earnings at ($0.59) EPS, FY2026 earnings at ($2.07) EPS, FY2027 earnings at ($2.32) EPS, FY2028 earnings at ($1.15) EPS and FY2029 earnings at ($1.40) EPS.

Precision BioSciences (NASDAQ:DTIL) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.09). Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 85.37%. The business had revenue of $10.84 million during the quarter, compared to analyst estimates of $4.05 million.

Several other brokerages also recently issued reports on DTIL. Weiss Ratings raised shares of Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 8th. Oppenheimer began coverage on shares of Precision BioSciences in a research note on Tuesday, June 9th. They set an “outperform” rating and a $20.00 price objective for the company. Finally, JonesTrading restated a “buy” rating and set a $30.00 price objective on shares of Precision BioSciences in a research report on Friday, April 17th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $32.25.

Precision BioSciences Stock Performance

NASDAQ:DTIL opened at $7.28 on Wednesday. The company has a current ratio of 14.02, a quick ratio of 14.02 and a debt-to-equity ratio of 0.29. The company has a market capitalization of $187.82 million, a P/E ratio of -1.98 and a beta of 1.27. The firm has a 50-day moving average price of $7.34 and a two-hundred day moving average price of $6.28. Precision BioSciences has a twelve month low of $3.53 and a twelve month high of $9.62.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DTIL. Geode Capital Management LLC grew its holdings in shares of Precision BioSciences by 5.5% during the second quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock worth $326,000 after buying an additional 4,025 shares in the last quarter. Bridgeway Capital Management LLC acquired a new position in shares of Precision BioSciences in the second quarter valued at approximately $260,000. Corient Private Wealth LLC purchased a new position in shares of Precision BioSciences during the second quarter valued at approximately $425,000. Vanguard Group Inc. lifted its stake in shares of Precision BioSciences by 21.5% during the third quarter. Vanguard Group Inc. now owns 492,596 shares of the company’s stock valued at $2,719,000 after buying an additional 87,242 shares during the period. Finally, Lynx1 Capital Management LP boosted its position in Precision BioSciences by 0.6% during the third quarter. Lynx1 Capital Management LP now owns 1,042,596 shares of the company’s stock worth $5,755,000 after acquiring an additional 6,545 shares during the last quarter. 37.99% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Precision BioSciences

Here are the key news stories impacting Precision BioSciences this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating on Precision BioSciences, signaling continued confidence in the company’s longer-term outlook despite expected losses. HC Wainwright Reiterates Buy Rating for Precision BioSciences
• Positive Sentiment: The analyst raised its EPS forecasts for fiscal 2028 to a loss of $1.15 per share from a loss of $1.91, and for fiscal 2029 to a loss of $1.40 from a loss of $2.15. These revisions suggest a better longer-term earnings trajectory than previously expected.
• Positive Sentiment: HC Wainwright also made a modest increase to its fiscal 2030 EPS forecast, to $1.09 from $1.08, keeping the possibility of eventual profitability in focus.
• Neutral Sentiment: Precision BioSciences is expected to report quarterly results on Thursday. Investors may remain cautious ahead of the release, particularly because the company’s prior quarter included a $0.75-per-share loss and earnings below analyst expectations. Precision BioSciences to Post Earnings on Thursday
• Negative Sentiment: HC Wainwright cut its EPS estimates for the second quarter to a loss of $0.57, the third quarter to a loss of $0.58, and the fourth quarter to a loss of $0.59. It also lowered its full-year 2026 forecast to a loss of $2.07 per share from a loss of $1.29.
• Negative Sentiment: The firm reduced its fiscal 2027 EPS forecast substantially, to a loss of $2.32 per share from a loss of $1.45, indicating expectations for deeper losses before the longer-term improvement. Precision BioSciences remains unprofitable, so these revisions could weigh on sentiment ahead of earnings.

Precision BioSciences Company Profile

Precision BioSciences is a clinical?stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno?oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin?out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.